hero image
Jan Hirsch, Ph.D. - UC San Diego. La Jolla, CA, US

Jan Hirsch, Ph.D. Jan Hirsch, Ph.D.

Professor of Clinical Pharmacy & Chair, Division of Clinical Pharmacy | UC San Diego

La Jolla, CA, UNITED STATES

Jan Hirsch's research interests are focused in the areas of pharmacoeconomics and outcomes research.

Media

Publications:

Documents:

Photos:

Videos:

Drug Development & Product Management I Jan D. Hirsch I Williams Ettouati I UC San Diego Information Session: MS in Drug Development & Product Management I Jan D. Hirsch I Williams Ettouati

Audio:

Social

Biography

Hirsch's research interests are focused in the areas of pharmacoeconomics and outcomes research. Specifically, i) assessing the full value (economic, clinical and humanistic) of pharmacy services and pharmaceuticals in clinical trials or observational studies across therapeutic areas and ii) integrating patient reported outcomes (PRO's) (e.g. burden elements, Health Related Quality of Life (HRQOL), satisfaction) into pharmaceutical and medical practice to improve patient management.

Hirsch has been the principal investigator (P.I.) for sequential studies, which resulted in the creation and validation of a disease-specific instrument to assess the impact of gout symptoms on patient HRQOL; the Gout Impact Scale (GIS). The GIS is an important contribution to clinical practice and research since the prevalence of gout is increasing and assessment of HRQOL using a disease specific instrument is prevalent for other diseases within rheumatology (e.g. arthritis), but no such instrument existed for gout - until the GIS.

She has also served as PI or Co-PI for several studies evaluating the clinical, economic and humanistic outcomes for patients receiving novel pharmacy services; hypertension, mental health, diabetes, HIV/AIDS, and immunizations. She was PI for a NIH-funded project examining the comparative effectiveness of pharmacist-provided medication therapy management (MTM) services within medical group practices.

Areas of Expertise (6)

Clinical Pharmacy Rheumatology Disease-specific Instruments Pharmaeutical Services Gout Impact Scale Pharmacoeconomics

Accomplishments (3)

Excellence in Teaching Award

UC San Diego
2004

Distinguished Alumni Award

University of South Carolina College of Pharmacy
2002

Outstanding Young Women of America

1984

Education (3)

University of South Carolina College of Pharmacy: Ph.D., Pharmacy Administration 1986

University of South Carolina College of Pharmacy: M.S., Pharmacy 1982

University of South Carolina College of Pharmacy: B.S., Pharmacy 1980

Affiliations (1)

  • Applied Pharmacoeconomic and Outcomes Research Forum

Media Appearances (3)

Jan Hirsch named founding dean of planned School of Pharmacy & Pharmaceutical Sciences

NBC San Diego  

2018-10-30

Jan Hirsch, Ph.D. – an acclaimed researcher, pharmacist and organizational leader – has been selected as director and founding dean of the planned School of Pharmacy & Pharmaceutical Sciences at the University of California, Irvine...

view more

Inaccurate Prescriptions, Usage Costs US $528.5 Billion Annually: UCSD Study

NBC San Diego  

2018-04-02

Watanabe led the study with Jan Hirsch, PhD, professor of clinical pharmacy and chair of the Division of Clinical Pharmacy at Skaggs School of Pharmacy, and Terry McInnis, MD, of Laboratory Corporation of America and the Get the Medications Right Institute...

view more

When drugs are wrong, skipped or make you sick: The cost of non-optimized medications

Science Daily  

2018-04-01

Watanabe led the study with Jan Hirsch, PhD, professor of clinical pharmacy and chair of the Division of Clinical Pharmacy at Skaggs School of Pharmacy, and Terry McInnis, MD, of Laboratory Corporation of America and the Get the Medications Right Institute...

view more

Articles (4)

Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic Journal of Managed Care & Specialty Pharmacy

Hirsch et al

2017

In 2012 U.S. diabetes costs were estimated to be $245 billion, with $176 billion related to direct diabetes treatment and associated complications. Although a few studies have reported positive glycemic and economic benefits for diabetes patients treated under primary care physician (PCP)-pharmacist collaborative practice models, no studies have evaluated the cost-effectiveness of an endocrinologist-pharmacist collaborative practice model treating complex diabetes patients versus usual PCP care for similar patients.

view more

Primary Care-based, Pharmacist -physician Collaborative Medication-therapy Management of Hypertension: A Randomized, Pragmatic Trial Clinical Therapeutics

Hirsch et al.

2014

A collaborative pharmacist-primary care provider (PharmD-PCP) team approach to medication-therapy management (MTM), with pharmacists initiating and changing medications at separate office visits, holds promise for the cost-effective management of hypertension, but has not been evaluated in many systematic trials. The primary objective of this study was to examine blood pressure (BP) control in hypertensive patients managed by a newly formed PharmD-PCP MTM team versus usual care in a university-based primary care clinic.

view more

Validation of a Patient Level Medication Regimen Complexity Index as a Possible Tool to Identify Patients for Medication Therapy Management Intervention Pharmacotherapy

Hirsch et al

2014

The Medication Regimen Complexity Index (MRCI) is a 65-item instrument that can be used to quantify medication regimen complexity at the patient level, capturing all prescribed and over-the-counter medications. Although the MRCI has been used in several studies, the narrow scope of the initial validation limits application at a population or clinical practice level.

view more

Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures International Journal of Clinical Practice

Hirsch et al

2014

Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, has demonstrated long-term benefits in gouty arthritis (GA) patients, who have contraindications for, or are unresponsive or intolerant of, non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine (two trials:β-RELIEVED [n = 228]; β-RELIEVED II [n = 226]). The trials collected different responses, including patient-reported outcomes (PRO). A composite response end-point (CRE) was used to interpret each patient's overall response to treatment.

view more

Contact